Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Podocytes and Proteinuria in ANCA-Associated Glomerulonephritis: A Case-Control Study.

van Daalen EE, Neeskens P, Zandbergen M, Harper L, Karras A, Vaglio A, de Zoysa J, Bruijn JA, Bajema IM.

Front Immunol. 2019 Jun 26;10:1405. doi: 10.3389/fimmu.2019.01405. eCollection 2019.

2.

A renal risk score for ANCA-associated glomerulonephritis.

Wester Trejo MAC, van Daalen EE, Berden AE, Wolterbeek R, van Es LA, Bos WJW, Ferrario F, Hagen EC, Jennette JC, Joh K, Neumann I, Noël LH, Pusey CD, Bruijn JA, Bajema IM.

Kidney Int. 2019 Jul;96(1):245. doi: 10.1016/j.kint.2019.01.046. No abstract available.

PMID:
31229031
3.

Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.

van Daalen EE, Jennette JC, McAdoo SP, Pusey CD, Alba MA, Poulton CJ, Wolterbeek R, Nguyen TQ, Goldschmeding R, Alchi B, Griffiths M, de Zoysa JR, Vincent B, Bruijn JA, Bajema IM.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):63-72. doi: 10.2215/CJN.04290417. Epub 2017 Nov 21.

4.

Antineutrophil cytoplasmic antibody-associated vasculitis and malignancy.

Wester Trejo MAC, Bajema IM, van Daalen EE.

Curr Opin Rheumatol. 2018 Jan;30(1):44-49. doi: 10.1097/BOR.0000000000000448. Review.

PMID:
28957961
5.

Incidence of Malignancy Prior to Antineutrophil Cytoplasmic Antibody-associated Vasculitis Compared to the General Population.

van Daalen EE, Rahmattulla C, Wolterbeek R, Bruijn JA, Bajema IM.

J Rheumatol. 2017 Mar;44(3):314-318. doi: 10.3899/jrheum.160885. Epub 2017 Jan 15.

PMID:
28089971
6.

Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.

van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, Bajema IM, Rahmattulla C.

Ann Rheum Dis. 2017 Jun;76(6):1064-1069. doi: 10.1136/annrheumdis-2016-209925. Epub 2016 Nov 29.

PMID:
27899372

Supplemental Content

Loading ...
Support Center